Literature DB >> 20053739

Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity.

Chantelle L Hood1, Jonathan Abraham, Jeffrey C Boyington, Kwanyee Leung, Peter D Kwong, Gary J Nabel.   

Abstract

Ebola virus (EBOV) cellular attachment and entry is initiated by the envelope glycoprotein (GP) on the virion surface. Entry of this virus is pH dependent and associated with the cleavage of GP by proteases, including cathepsin L (CatL) and/or CatB, in the endosome or cell membrane. Here, we characterize the product of CatL cleavage of Zaire EBOV GP (ZEBOV-GP) and evaluate its relevance to entry. A stabilized recombinant form of the EBOV GP trimer was generated using a trimerization domain linked to a cleavable histidine tag. This trimer was purified to homogeneity and cleaved with CatL. Characterization of the trimeric product by N-terminal sequencing and mass spectrometry revealed three cleavage fragments, with masses of 23, 19, and 4 kDa. Structure-assisted modeling of the cathepsin L-cleaved ZEBOV-GP revealed that cleavage removes a glycosylated glycan cap and mucin-like domain (MUC domain) and exposes the conserved core residues implicated in receptor binding. The CatL-cleaved ZEBOV-GP intermediate bound with high affinity to a neutralizing antibody, KZ52, and also elicited neutralizing antibodies, supporting the notion that the processed intermediate is required for viral entry. Together, these data suggest that CatL cleavage of EBOV GP exposes its receptor-binding domain, thereby facilitating access to a putative cellular receptor in steps that lead to membrane fusion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053739      PMCID: PMC2826059          DOI: 10.1128/JVI.02151-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.

Authors:  Graham Simmons; Rouven J Wool-Lewis; Frédéric Baribaud; Robert C Netter; Paul Bates
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

3.  C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.

Authors:  Carmen P Alvarez; Fátima Lasala; Jaime Carrillo; Oscar Muñiz; Angel L Corbí; Rafael Delgado
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

4.  Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins.

Authors:  Kathryn L Schornberg; Charles J Shoemaker; Derek Dube; Michelle Y Abshire; Sue E Delos; Amy H Bouton; Judith M White
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-28       Impact factor: 11.205

5.  Comprehensive analysis of ebola virus GP1 in viral entry.

Authors:  Balaji Manicassamy; Jizhen Wang; Haiqing Jiang; Lijun Rong
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses.

Authors:  S Y Chan; C J Empig; F J Welte; R F Speck; A Schmaljohn; J F Kreisberg; M A Goldsmith
Journal:  Cell       Date:  2001-07-13       Impact factor: 41.582

7.  A system for functional analysis of Ebola virus glycoprotein.

Authors:  A Takada; C Robison; H Goto; A Sanchez; K G Murti; M A Whitt; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

8.  Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry.

Authors:  Ayato Takada; Kouki Fujioka; Makoto Tsuiji; Akiko Morikawa; Nobuaki Higashi; Hideki Ebihara; Darwyn Kobasa; Heinz Feldmann; Tatsuro Irimura; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.

Authors:  Zhi-yong Yang; Bimal K Chakrabarti; Ling Xu; Brent Welcher; Wing-pui Kong; Kwanyee Leung; Amos Panet; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza virus hemagglutinin.

Authors:  J M White; I A Wilson
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

View more
  69 in total

1.  Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

Authors:  John Misasi; Kartik Chandran; Jin-Yi Yang; Bryden Considine; Claire Marie Filone; Marceline Côté; Nancy Sullivan; Giulia Fabozzi; Lisa Hensley; James Cunningham
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Structural basis for Marburg virus neutralization by a cross-reactive human antibody.

Authors:  Takao Hashiguchi; Marnie L Fusco; Zachary A Bornholdt; Jeffrey E Lee; Andrew I Flyak; Rei Matsuoka; Daisuke Kohda; Yusuke Yanagi; Michal Hammel; James E Crowe; Erica Ollmann Saphire
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

3.  Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Authors:  John Misasi; Morgan S A Gilman; Masaru Kanekiyo; Miao Gui; Alberto Cagigi; Sabue Mulangu; Davide Corti; Julie E Ledgerwood; Antonio Lanzavecchia; James Cunningham; Jean Jacques Muyembe-Tamfun; Ulrich Baxa; Barney S Graham; Ye Xiang; Nancy J Sullivan; Jason S McLellan
Journal:  Science       Date:  2016-02-25       Impact factor: 47.728

4.  The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection.

Authors:  Eva Mittler; Larissa Kolesnikova; Bettina Hartlieb; Robert Davey; Stephan Becker
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

5.  Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses.

Authors:  Joseph D Bazzill; Sabrina M Stronsky; Laura C Kalinyak; Lukasz J Ochyl; Jesse T Steffens; Sean A van Tongeren; Christopher L Cooper; James J Moon
Journal:  Nanomedicine       Date:  2018-11-22       Impact factor: 5.307

Review 6.  Filovirus entry into cells - new insights.

Authors:  Emily Happy Miller; Kartik Chandran
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

7.  Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Authors:  Rebecca J Grant-Klein; Louis A Altamura; Catherine V Badger; Callie E Bounds; Nicole M Van Deusen; Steven A Kwilas; Hong A Vu; Kelly L Warfield; Jay W Hooper; Drew Hannaman; Lesley C Dupuy; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.

Authors:  Osvaldo Martinez; Lee Tantral; Nirupama Mulherkar; Kartik Chandran; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

9.  Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.

Authors:  Hatem A Elshabrawy; Jilao Fan; Christine S Haddad; Kiira Ratia; Christopher C Broder; Michael Caffrey; Bellur S Prabhakar
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

Review 10.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.